Full history for every metric is available with a Kvantra account
InhaleRx Limited (IRX.AX)
Key financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Operating profit | AUD m | -1 | -1 | |||||
| Net profit | AUD m | -2 | -1 | -1 | -2 | -1 | -1 | -1 |
| EPS reported | AUD | -0.01 | -0.01 | |||||
| Operating cashflow per share | AUD | -0.00 | -0.00 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.00 | -0.00 | |||||
| Free cash flow | AUD m | -0 | -0 | |||||
| Net debt | AUD m | -0 | -0 | |||||
| Book value equity | AUD m | - | - | |||||
| Book value per share | AUD | -0.00 | - | |||||
| Number of shares | m | 213.45 | 213.45 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -116.78 | -93.42 | |||||
| P/S LTM | x | 22.29 | 8.95 | |||||
| P/FCF LTM | x | -20.26 | -23.50 | |||||
| EV/EBITDA LTM | x | -6.52 | -3.03 | |||||
| EV/Sales LTM | x | 21.81 | 8.76 | |||||
| Earnings Yield LTM | % | -17.08% | -21.35% | |||||
| FCF Yield | % | -4.94% | -4.26% | |||||
| Quality | ||||||||
| ROE | % | 1994.9% | -424.30% | |||||
| ROIC | % | 3073.5% | 3073.5% | |||||
| Operating margin | % | -396.04% | -396.04% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -110.05% | -110.05% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -72.17% | -13.12% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.83 | -0.87 | |||||
| Net Debt/EBITDA | x | 0.14 | 0.14 | |||||
| EBIT/Net interest | x | -15.09 | -15.09 | |||||
| Net debt/market cap | % | -2.15% | -2.10% | |||||
| Net debt/Equity | x | - | - | |||||
| Gross debt/equity | x | - | - | |||||
Company overview
Established in 2016 and headquartered in Sydney, Australia, InhaleRx Limited is an Australian company primarily engaged in advancing and bringing to market medical drug delivery systems. The firm also dedicates efforts to developing specialized inhaled drug formulations. A notable product within its portfolio is the Medihale inhaler, a distinctive sealed-pod device engineered for compatibility with its inhaled medications. This entity formerly traded as Lifespot Health Ltd, officially adopting the name InhaleRx Limited in October 2021.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
InhaleRx Limited (IRX.AX)
Established in 2016 and headquartered in Sydney, Australia, InhaleRx Limited is an Australian company primarily engaged in advancing and bringing to market medical drug delivery systems. The firm also dedicates efforts to developing specialized inhaled drug formulations. A notable product within its portfolio is the Medihale inhaler, a distinctive sealed-pod device engineered for compatibility with its inhaled medications. This entity formerly traded as Lifespot Health Ltd, officially adopting the name InhaleRx Limited in October 2021.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free